DK2424564T3 - A vaccine for the prevention or treatment of a respiratory pathology allergendrevet - Google Patents
A vaccine for the prevention or treatment of a respiratory pathology allergendrevet Download PDFInfo
- Publication number
- DK2424564T3 DK2424564T3 DK10715245T DK10715245T DK2424564T3 DK 2424564 T3 DK2424564 T3 DK 2424564T3 DK 10715245 T DK10715245 T DK 10715245T DK 10715245 T DK10715245 T DK 10715245T DK 2424564 T3 DK2424564 T3 DK 2424564T3
- Authority
- DK
- Denmark
- Prior art keywords
- pertussis
- ova
- live attenuated
- bpze1
- bordetella pertussis
- Prior art date
Links
- 230000007170 pathology Effects 0.000 title claims description 35
- 238000011282 treatment Methods 0.000 title claims description 8
- 230000002265 prevention Effects 0.000 title claims 2
- 229960005486 vaccine Drugs 0.000 title description 16
- 230000000241 respiratory effect Effects 0.000 title description 2
- 241000588832 Bordetella pertussis Species 0.000 claims description 79
- 230000002238 attenuated effect Effects 0.000 claims description 63
- 239000013566 allergen Substances 0.000 claims description 49
- 229940066827 pertussis vaccine Drugs 0.000 claims description 32
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 18
- 101710110818 Dermonecrotic toxin Proteins 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 201000009961 allergic asthma Diseases 0.000 claims description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 230000002009 allergenic effect Effects 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 description 57
- 229940092253 ovalbumin Drugs 0.000 description 57
- 208000026935 allergic disease Diseases 0.000 description 33
- 206010020751 Hypersensitivity Diseases 0.000 description 32
- 230000007815 allergy Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 27
- 230000004044 response Effects 0.000 description 27
- 206010070834 Sensitisation Diseases 0.000 description 21
- 230000008313 sensitization Effects 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 20
- APUIQTDTBPKWKE-RNPGEKFLSA-N (2r,6s)-6-[[(4r)-4-[[(2s)-2-[2-[[(1r,2s,3r,4r,5r)-4-acetamido-2-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2r)-2-am Chemical compound O([C@@H]1[C@H]2CO[C@H](O2)[C@H](NC(C)=O)[C@H]1OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H](N)C(O)=O)C(=O)NC(=O)[C@H](N)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O APUIQTDTBPKWKE-RNPGEKFLSA-N 0.000 description 17
- 108090000176 Interleukin-13 Proteins 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 102000000743 Interleukin-5 Human genes 0.000 description 11
- 108010002616 Interleukin-5 Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000037452 priming Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 210000003979 eosinophil Anatomy 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 201000005702 Pertussis Diseases 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 230000001235 sensitizing effect Effects 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000037883 airway inflammation Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005713 exacerbation Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101150103308 ampG gene Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000000304 virulence factor Substances 0.000 description 4
- 230000007923 virulence factor Effects 0.000 description 4
- 206010014950 Eosinophilia Diseases 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000037884 allergic airway inflammation Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 208000012657 Atopic disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 101000878581 Aplysia californica Feeding circuit activating peptides Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102000044708 Eosinophil peroxidases Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 101150099497 dnt gene Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000019183 negative regulation of isotype switching Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
DESCRIPTION
FIELD OF THE INVENTION
[0001] The present invention relates to a vaccine for prophylaxis or treatment of an allergen-driven airway pathology. BACKGROUND OF THE INVENTION
[0002] The pathogenesis of allergic asthma remains unclear, however, the current understanding involves the expansion of CD4+ Th2 cells, and a breakdown in tolerance to otherwise innocuous environmental allergens (Romagnani et al. J Allergy Clin Immunol 2004;113(3):395-400). Genetic predisposition, coupled with environmental influences appears to affect the regular suppression of Th2-mediated responses. It has been hypothesized that abnormalities in the maturation of the lung during fetal and neonatal development may render the airways more susceptible to environmental allergens, favoring polarization towards the Th2 phenotype and thus, predisposing the individual to atopy and asthma. Allergen-driven production of IL-4, IL-5 and IL-13 are typical of allergic pathologies and the secretion of such Th2-cytokines initiates isotype class-switching of B cells towards IgE, increased mucus production and recruitment of eosinophils to the airways. Since CD4+ Th2 cells represent a co-ordinating cell type in some allergies, it was suggested that the induction of counterbalancing responses might prevent the subsequent development of atopic disease. According to this modification of Strachan's hygiene hypothesis (Romagnani et al. Int Arch Allergy Immunol 1992;98(4):279-85), microbial exposure may activate innate immune pathways that alter Th1, Th2 and Treg responses. This results in the suppression of T helper 2 cell expansion, and a consequent inhibition of isotype switching to IgE. However, several studies have suggested that viral and bacterial infections play a role in exacerbation of respiratory disease. For example, respiratory syncytial virus and Th1 inducing virulent Bordetella pertussis infection (Ennis et al. Clin Exp Allergy 2004;34(9): 1488-97) exacerbate allergic inflammation in animal models. Gram-negative B. pertussis causes whooping cough, a severe respiratory disease responsible for significant infant morbidity and mortality worldwide. Although immunizations with either killed whole cell vaccines (Pw) or more recent acellular subunit vaccines (Pa) have had success, a re-emergence of the disease in young adults has been reported (Das P. Lancet Infect Dis 2002;2(6):322). Typically, B. pertussis does not acutely affect this age group; however, infected adults can act as reservoirs, and increase the likelihood of infants contracting the disease prior to vaccination. Most current vaccination regimes require three doses, beginning at 2 months of age necessitating 6 months for optimal protection. Therefore, there is a need for vaccines that induce strong protection against B. pertussis in neonates.
Virulent B. pertussis infection exacerbates airway pathology in a murine model of allergen driven inflammation, despite the induction of Th1 immunity (Ennis et al. Clin Exp Allergy 2004;34(9): 1488-97). Th2 inducing Pa vaccines protect against B. pertussis-induced exacerbation of allergic asthma, but induce IL-13 both at a systemic and local level (Ennis et al. Clin Diagn Lab Immunol 2005;12(3):409-17). In contrast, systemic immunization with Th 1 inducing Pw inhibits allergic airway responsiveness (Mills et al. Dev Biol Stand. 1998;95:31-41), suggesting that protection from allergen-driven pathology is not simply modulation of Th1/Th2 responses, but is associated with the degree of airway damage at the time of priming, such that allergen priming via the respiratory tract airways during breakdown of the airway epithelial mesenchymal unit may be a more significant factor than Th1/Th2/Treg polarization.
Recently, a genetically-attenuated live vaccine against B. pertussis, BPZE1, has been developed as a candidate neonatal vaccine against whooping cough (Mielcarek et al. PLoS Pathog 2006;2(7):e65). This live recombinant B. pertussis strain induces strong local and systemic immune responses upon intranasal delivery. Administration via the nasal route mimics natural infection and is expected to promote long-lasting immunity in children from 1 month of age (Mascart et al. J Immunology 2003; 170(1): 1504-9). Three virulence factors have been targeted for attenuation; pertussis toxin, tracheal cytotoxin and dermonecrotic toxin. Using allelic exchange, genes encoding these toxins were deleted or replaced with genetically inactivated analogues in order to induce protection, without the severe pathology associated with wild-type infection. However, the influence of BPZE1 administration on third party allergen priming and allergen induced pathology is not known.
SUMMARY OF THE INVENTION
[0003] The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
[0004] Disclosed herein is a method for prophylaxis or treatment of an allergen-driven airway pathology in a subject, comprising administering to said subject an effective amount of a live attenuated Bordetella pertussis vaccine, wherein said live attenuated
Bordetella pertussis vaccine is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT).
[0005] The present invention also relates to the use of a live attenuated Bordetella pertussis vaccine, which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) in the manufacture of a medicament for prophylaxis or treatment of an allergen-driven airway pathology.
DETAILED DESCRIPTION OF THE INVENTION
[0006] Examples of allergen-driven airway pathology are allergic asthma, Hay fever, interstitial lung diseases including pulmonary fibrosis.
Interstitial lung diseases including pulmonary fibrosis, may be caused by occupational or environmental exposures. Without wishing to be bound by theory, a live attenuated Bordetella pertussis vaccine, which is deficient for TCT, PTX, and DNT would reduce airway damage and remodelling during a period of environmental exposure (to the agent triggering Interstitial lung diseases) and would also protect against virulent B. pertussis exacerbation of pulmonary fibrosis.
[0007] By "subject" it is meant a human. Typically the subject is a neonate, an infant or an adult.
Live attenuated Bordetella pertussis vaccines which are deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) have been described in W02007/104451 and in Mielcarek et al. (PLoS Pathog 2006;2(7):e65).
Recent advances in the understanding of B. pertussis virulence at the molecular level have allowed to rationally design a strategy for attenuation by removing or altering genes that are involved in the pathogenesis of whooping cough. Three virulence factors were genetically targeted: tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT).
[0008] TCT is responsible for the destruction of ciliated cells in the trachea of infected hosts and may thus be involved in the cough syndrome. TCT is a breakdown product of peptidoglycan in the cell wall of Gram-negative bacteria, which generally internalize it into the cytosol by the AmpG transporter protein to be re-utilized during cell wall biosynthesis. B. pertussis AmpG is inefficient in the internalization of peptidoglycan breakdown products. The B. pertussis ampG gene can be replaced by E. coli amps. The resulting strain expressed less than 1% residual TCT activity. Any heterologous ampG gene from gram-negative bacteria that release very small amounts of peptidoglycan fragments into the medium, can be used in the present invention. Examples of suitable heterologous ampG gene include, but are not limited to ampG gene from Escherichia coli, Salmonella, Enterobacteriaceae, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, Legionella. PTX is a major virulence factor responsible for the systemic effects of B. pertussis infections and is composed of an enzymatically active moiety, called S1, and a moiety responsible for binding to target cell receptors. It is also one of the major protective antigens. The natural pfx genes can be replaced by a mutated version coding for an enzymatically inactive toxin. This can be achieved by replacing Arg-9 by Lys, and Glu-129 by Gly in S1, two key residues involved in substrate binding and catalysis, respectively. Allelic exchange can be used to first delete the pfxoperon, and then to insert the mutated version.
[0009] The presence of the relevant toxin in the B. pertussis culture supernatants can be detected by immunoblot analysis.
Other mutations can also be made such as those described in U.S. Patent 6,713,072, as well as any known or other mutations able to reduce the toxin activity to undetectable levels.
Allelic exchange can also be used to remove the dnt gene. Although the role of DNT in the virulence of B. pertussis is not certain, it has been identified as an important toxin in the closely related species Bordetella bronchiseptica and displays lethal activity upon injection of minute quantities.
In a preferred embodiment, the live attenuated Bordetella pertussis vaccine is the BPZE1 strain.
The BPZE1 strain has been deposited with the Collection Nationale de Cultures de Microorganismes (CNCM, Institut Pasteur, 25 rue du Docteur Roux, F-75724 Paris Cedex 15, FRANCE) on March 9, 2006 under the number CNCM I-3585.
[0010] Typically, live attenuated Bordetella pertussis vaccines of the invention may also carry heterologous antigens. The live attenuated Bordetella pertussis vaccines may be used as vector, to bear at least one further heterologous nucleic acid sequence encoding a protein of interest. Typically, the protein encoded by at least one further heterologous nucleic acid sequence is a protein for which the expression is desired in the respiratory tract. Typically, the protein of interest may be an antigen, such as a viral or a bacterial antigen, against which an immune response is desired. Examples of live attenuated Bordetella pertussis vaccines carrying heterologous antigens have been disclosed for example by Si Ying Ho et al. (Infection and Immunity, 2008, 76(1), 111-119).
[0011] Formulation of the vaccines of the present invention can be accomplished using art recognized methods. The amount of vaccines of the invention to be administered to a subject and the regime of administration can be determined in accordance with standard techniques well known to those of ordinary skill in the pharmaceutical and veterinary arts taking into consideration such factors as the adjuvant (if present), the age, sex, weight, species and condition of the particular subject and the route of administration. The administration of the vaccine is usually in a single dose. Alternatively, the administration of the vaccine of the invention is made a first time (initial vaccination), followed by at least one recall (subsequent administration), with the vaccine.
[0012] Typically the vaccines can be administered by nasal administration or by inhalation. This type of administration is low in costs and enables the colonization by the live attenuated Bordetella pertussis vaccine of the invention of the respiratory tract. Nasal administration may be accomplished with a live attenuated Bordetella pertussis vaccine under the form of liquid solution, suspension, emulsion. Solutions and suspensions are administered as drops. Solutions can also be administered as a fine mist from a nasal spray bottle or from a nasal inhaler. Gels are dispensed in small syringes containing the required dosage for one application. Inhalation may be accomplished with a live attenuated Bordetella pertussis vaccine under the form of solutions, suspensions, and powders; these formulations are administered via an aerosol, droplets or a dry powder inhaler. The powders may be administered with insufflators or puffers.
[0013] In the following, the invention vull be illustrated by means of the following example as well as the figures.
FIGURE LEGENDS
[0014]
Figure 1. Attenuated B. pertussis BPZE1 reduces the severity of airway pathology induced by sensitizing allergen. Representative morphological changes at 38 days in bronchiolar transverse sections of lungs from (A) Non-sensitized, (B) OVA-sensitized, (C) OVA-sensitized and infected with B. pertussis, (D) OVA-sensitized and immunized with BPZE1. Airway inflammation was detected using haematoxylin and eosin (H&E) staining of fixed lung sections. Original magnification A, C, E & G x100. B, D, F&HX400.
Figure 2. Attenuated B. pertussis BPZE1 reduces the severity of mucus hyperplasia to sensitizing allergen. Representative morphological changes at 37 days in transverse sections of bronchioles from (A) non-sensitized, (B) OVA-sensitized, (C) OVA-sensitized and infected with B. pertussis, (D) OVA-sensitized and vaccinated with BPZE1. Airway inflammation was detected using combined Discombes/Alcian blue/PAS staining on lung sections. Original magnification x400.
Figure 3. Attenuated B. pertussis BPZE1 reduces the cell infiltrate ofBAL fluid. Effect of virulent BPSM infection, attenuated BPZE1 challenge and/or OVA sensitization on BAL composition 24h after final OVA exposure. Negative controls were sham infected/sensitized with saline. BAL fluid was examined for the total cell number (A), or the presence of neutrophils (B), eosinophils (C) or lymphocytes (D). Results are expressed as mean ± S.E.M. of cell number. *P<0.05.
Figure 4. Attenuated B. pertussis BPZE1 reduces allergen-induced IgE. OVA-specific IgE in serum elicited in response to OVA sensitization and/or challenge with virulent (BPSM) or attenuated (BPZE1) B. pertussis. Sera were collected on day 38 and OVA-specific serum IgE levels were measured by ELISA. Concentrations below 100pg/ml were considered negative. Results are expressed as mean antibody concentrations ± S.E.M. P<0.05.
Figure 5. Cell-mediated immune responses from splenocytes to OVA, elicited by OVA sensitization 10 days following prior exposure to attenuated (BPZE1) or virulent (BPSM) B. pertussis infection. Negative symbols indicate sham sensitization or challenge with PBS. Cytokine responses from similar cultures assayed are shown for (A) IL-5, (B) IL-10, (C) IL-13 and (D) IFN-y. T-cell proliferation (E) represents Acpm of spleen proliferation against OVA at 200pg/ml following subtraction of background typically 2000-4000cpm. Results are expressed as mean ± S.E.M.
Table I. Summary of pathological features of B. pertussis /allergen sensitization. Features of airway inflammation in non-sensitized (Control), OVA-sensitized (OVA), BPZE1-immunized sensitized mice (ZeOVA) or BPSM-infected sensitized mice (SmOVA).
EXAMPLE
ABSTRACT
[0015] This predinical study examined whether the candidate B. pertussis vaccine BPZE1 influences third party allergen priming and pathology, using previously characterized animal models. Unlike virulent wildtype strains, live attenuated BPZE1 did not exacerbate but protected against allergen-driven pathology.
Abbreviations used [0016] OVA: Ovalbumin; BAL: Bronchoalveolar lavage; BPZE1: live attenuated Bordetella pertussis', Pa: Acellular pertussis vaccine; Pw: Whole-cell pertussis vaccine
MATERIALS
Immunization, sensitization and airway delivery of OVA and B. pertussis [0017] Eight- to twelve-week old, female BALB/c mice (Harlan, Oxon, UK) were used and maintained according to the regulations and guidelines of the Irish Department of Health, and the Research Ethics Committee of the National University of Ireland, Maynooth. Mice were exposed to live virulent or attenuated bacteria, and sensitized to allergen during infection. Virulent B. pertussis BPSM or attenuated BPZE1 were cultured as previously described (Mills et al. Dev Biol Stand. 1998;95:31-41). Attenuated or virulent strains at mid-log growth were administered to mice by aerosol. At the peak of infection (1 Od) and at 24d, mice were sensitized by intra-peritoneal injection of 100pg/ml ovalbumin (OVA) in adjuvant (Alumlmject™, Pierce, 111). Mice were challenged intra-nasally with OVA (50pg/ml) on days 24, 35, 36 and 37. Various control groups received sham delivery of sterile PBS in place of the active agent (Ennis et al. Clin Exp Allergy 2004;34(9): 1488-97).
Bronchoalveolar Lavage (BAL) and Respiratory Tract Histology [0018] On 37d, mice were sacrificed by lethal injection of sodium pentobarbital and BAL fluid collected (Ennis et al. Clin Exp Allergy 2004;34(9): 1488-97). Total leukocytes and differential cell counts were performed as described, using Diff Quik/Rapi-Diff II™ (Triangle Biomedical Sciences, NC, USA.). Lungs from non-lavaged mice were removed and fixed in 10% (v/v) formalin/PBS, embedded in paraffin, sectioned and stained with haemotoxylin/eosin (H&E), alcian blue (identification of mucus), Discombes (identification of eosinophils), or periodic acid-Schiff (for assessment of basement membrane thickness). Histopathological changes were graded according to an established semi-quantitative scoring system as mild, moderate or severe. Pathology was scored by two independent observers without prior knowledge of the treatment group as previously described (Ennis et al. Clin Diagn Lab Immunol 2005;12(3):409-17). T cell Proliferation assay [0019] Splenocytes from mice were prepared as previously described (Mahon et al. J Exp Med 1997; 186(11):1843-1851) and incubated for 72h with either medium (negative control), OVA (200pg/ml), or concanavalin A (5pg/ml). Supernatants were removed at 48h for cytokine analysis, and cultures received fresh medium. Cells were incubated for the final 6h with [3H]-thymidine and proliferation was measured by radioactivity incorporated by liquid scintillation.
Measurement of cytokines and antibody responses [0020] Analysis of IL-5, IL-10, IL-13 and IF N-γ from BAL fluid and splenocyte supernatant was carried out using Cytometric Bead Array Flex Sets (BD Biosciences, Franklin Lakes, NJ) according to manufacturer's instructions, and analysed by flow cytometry (Becton-Dickinson, NJ, USA). Standard curves and raw data were generated for each cytokine using FCAP Array v1.0.1 software (BD Biosciences). OVA-specific serum IgE was measured by ELISA as previously described ( Morokata Tet al. Immunology 1999;98(3):345-351) using a rat anti-mouse IgE monoclonal antibody (BD Pharmingen, San Diego, CA, USA). IgE concentration was expressed as pg/ml after comparison to murine IgE standards (BD, Pharmingen, San Diego, CA, USA).
Statistical analysis [0021] Values for all measurements were expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed using GraphPad Prism™ software (GraphPad, San Diego, CA). Comparison was made using the Kruskal Wallis test, or the Mann Whitney test as appropriate. Significance was denoted by P value <0.05.
RESULTS
The attenuated B. pertussis BPZE1 prevents exacerbated OVA-driven allergic airway pathology [0022] Virulent B. pertussis can exacerbate third party allergen priming in animal models (Ennis et al. Clin Exp Allergy 2004;34(9): 1488-97) and has been associated with exacerbation of allergy in humans (Harju et al. Thorax 2006;61 (7):579-584).To assess the influence of attenuated B. pertussis on third party allergen priming, mice were primed with virulent or attenuated strains of B. pertussis, and sensitized to OVA at the peak of bacterial carriage (a model previously shown to uncover the influence of infection on allergen-driven inflammation). In the absence of infection, OVA sensitized mice exhibited typical peribronchial and perivascular inflammation at day 38, which was not observed in naive control mice (Fig 1Aand B). At this time point, pathology due to virulent bacterial infection alone has resolved. Priming at the peak of virulent B. pertussis infection enhanced airway pathology when compared to OVA sensitization alone, with mice displaying epithelial hyperplasia and moderate mucus metaplasia (Fig. 1C). In contrast, minimal pathology was observed in sensitized mice infected with attenuated BPZE1, compared to those sensitized to OVA alone (Fig. 1D). An examination of mucus-containing goblet cells demonstrated that prior immunization with BPZE1 in OVA-sensitized mice reduced mucus secretion and hyperplasia, compared to those sensitized to OVA alone (Fig. 2). Thus unlike infection with virulent B. pertussis, immunization with the candidate live attenuated B. pertussis vaccine BPZE1 did not enhance, but reduced the pathology associated with allergen sensitization.
The attenuated B. pertussis vaccine strain BPZE1 prevents OVA-driven allergic airway inflammation [0023] Immunization with live attenuated B. pertussis BPZE1 moderated the quality of the OVA-induced inflammatory influx to the respiratory tract. Control mice showed minimal cellularity in bronchoalveolar lavage (Fig. 3), whereas OVAsensitization/challenge resulted in significant infiltration by inflammatory cells (>3 x 106 cells, Fig. 3A, p<0.05). There were few remarkable differences in the numbers of lymphocytes or neutrophils. BPZE1 immunization alone did not support a neutrophil infiltration at 38d and infiltration of neutrophils in combined BPZE1/OVAsensitized mice was typically lower than either OVAalone or in combination with virulent bacteria, however this did not achieve statistical significance in this study. The key observations were that prior infection with virulent B. pertussis increased cellular infiltration compared to sensitization by OVA alone accompanied by increased eosinophilia (Fig. 3C) as previously observed (Ennis et al. Clin Exp Allergy 2004;34(9): 1488-97). However in marked contrast immunization with live attenuated BPZE1 prior to OVA sensitization resulted in significantly reduced OVA driven eosinophil infiltration of the airways (Fig. 3C, p<0.05). Thus, the candidate live attenuated B. pertussis vaccine BPZE1 prevents OVA-driven allergic airway eosinophilia- a key feature of inflammation in this model.
The candidate live B. pertussis vaccine BPZE1 does not enhance serum IgE responses to sensitizing allergen [0024] OVA sensitization in mice is known to induce IgE and a powerful specific Th2 response, whereas B. pertussis infection induces a strong Th1 response. However, pertussis toxin alone can elevate IgE concentrations. Therefore, it was important to explore whether attenuated BPZE1 had an adjuvant effect or enhanced allergen-specific IgE. The influence of BPZE1 on allergic sensitization was examined by measuring the concentration of OVA-specific IgE in serum from mice sensitized to OVA, infected with BPSM, immunized with BPZE1, or receiving combinations of these treatments (Fig. 4). OVA sensitization induced significant levels of IgE as is well documented. Previously, a significant increase in OVA-specific IgE following infection with virulent B. pertussis W28 was observed in OVA-sensitized mice (Ennis et al. Clin Exp Allergy 2004;34(9):1488-97). IgE responses in mice exposed to attenuated BPZE1 prior to OVA sensitization did not differ significantly to those receiving OVA alone. However, in marked contrast, attenuated BPZE1 immunization resulted in significantly reduced induction (p<0.05) of OVA-induced IgE compared to mice infected with virulent BPSM in combination with OVA sensitization (Fig. 4). Therefore, the candidate live attenuated B. pertussis vaccine BPZE1 delivered prior to allergen priming demonstrated no enhanced IgE response as observed with B. pertussis W2811 and BPSM.
The live attenuated B. pertussis vaccine BPZE1 modulates recall cytokine responses to sensitizing allergen [0025] It is clear that attenuated BPZE1 has a radically different effect on allergen-driven airway pathology compared to virulent B. pertussis. In order to uncover the mechanistic basis of this effect, the influence of bacterial exposure on the pattern of allergen-induced immune responses was characterized. Allergen-specific cytokine induction by spleen cell preparations was assessed following immunization with BPZE1 and OVA sensitization/challenge in order to evaluate the influence of BPZE1 on allergen-induced priming. As expected, OVA sensitization alone induced high levels of the Th2 cytokines IL-5 and IL-13 (Fig. 5) on recall to OVA. Neither virulent BPSM nor attenuated BPZE1 alone induced any recall response to OVA (Fig. 5E), but did produce strong Th1 responses to B. pertussis antigens. BPSM challenge did not modulate the immune response to sensitizing allergen, with no significant reduction in OVA specific IL-5, IL-13 or proliferative responses observed in mice co-sensitized to OVA, and no significant increase in IFN-γ (Fig 5). In contrast, attenuated BPZE1 altered the pattern of cytokines induced by sensitizing allergen. BPZE1 significantly reduced the levels of OVA-induced IL-5 (p<0.005) and IL-13 (p< 0.05), as well as OVA specific proliferative responses (p<0.001), but induced significantly increased IFN-γ in response to OVA(p< 0.05). In summary, BPZE1 did not promote Th2 cytokine induction to third party antigen but rather modulated this to a Th1 like response.
DISCUSSION
[0026] The present study used combined infection/sensitization models to demonstrate that an attenuated strain of B. pertussis, BPZE1, did not enhance but reduced allergen-driven airway pathology. Attenuated B. pertussis reduced allergen-driven lung eosinophilia and decreased the severity of airway inflammation. Furthermore, BPZE1 prevented an increase in OVA-induced IL-5 and IL-13 and modulated recall responses to allergen to a Th 1 like response. BPZE1 demonstrated reduced allergen-induced serum IgE responses when compared to mice infected with virulent B. pertussis prior to OVA sensitization (see Table I). Taken together these data demonstrate that attenuated BPZE1 does not exacerbate allergen-induced airway pathology in a murine model and supports the use of this candidate vaccine for populations where atopy is prevalent.
[0027] The hygiene hypothesis suggests that Th1-inducing infections may have an inhibitory effect on the development of atopy. However, previous studies have demonstrated that virulent B. pertussis enhances the severity of airway pathology (Ennis et al. Clin Exp Allergy 2004;34(9):1488-97) despite induction of Th1 immunity. In contrast, systemic immunization with a Th1-inducing Pw vaccine inhibited allergic airway responsiveness, suggesting that protection from allergen-driven pathology is linked not just to CD4+ T cell profile, but also to the degree of airway damage at the time of priming.
[0028] The purpose of this study was to investigate whether immunization with a genetically attenuated strain of B. pertussis could protect against OVA-induced airway inflammation. Previously, the potential of other vaccines to moderate the risk of atopy has been investigated and a number of studies have found an inverse relationship between immunization and an increased risk of allergic disease. Ennis et al found that a Pw vaccine protected against B. pertussis-exacerbation of OVA-induced airway hyperresponsiveness in a murine model of allergic airway inflammation (Mills et al. Dev Biol Stand. 1998;95:31-41). Likewise, Gruber et al found no allergy-promoting effect in response to common childhood vaccines including pertussis vaccines (Griiber et al. Allergy 2008;63(11):1464-72). The relationship between childhood immunization and the development of atopic diseases in a population-based sample of 718 adolescents found that live attenuated vaccines inhibited the development of asthma and allergic diseases (Martignon et al. Pediatr Allergy Immunol. 2005; 16(3): 193-200). The current study demonstrates that the vaccine candidate BPZE1 suppresses allergen-driven pathology through a mechanism that modulates cell-mediated responses against OVA at both a mucosal and systemic level. IL-5-mediated recruitment of eosinophils to the lung contributes to allergen-induced airway pathology by generating potent cytotoxic products, including major basic protein (MBP) and eosinophil peroxidase, which collectively contribute to tissue damage (Gleich G. J Allergy Clin Immunol 2000;105(4):651-63). Infection with virulent B. pertussis exacerbates the extent of the OVA-induced inflammatory influx to the respiratory tract, with an increase in eosinophils (Fig. 3C), accompanied by a marked increase in the severity of airway pathology (Fig. 1G). Conversely, administration of attenuated BPZE1 prior to allergen sensitization resulted in a significant reduction in eosinophil infiltration. This study demonstrates that BPZE1 prevents the adjuvant-associated increase in OVA-induced IL-5 (Fig. 1A) seen when animals are infected with virulent B. pertussis strains. IL-13 also contributes to the pathogenesis of asthma by promoting Th2 responses, increasing eosinophil recruitment, and contributing to IgE-mediated inflammation (Humbert et al. J Allergy Clin Immunol. 1997;99(5):657-65; Temann et al. Am J Respir Cell Mol Biol 1997;16(4):471-8). Attenuated BPZE1 significantly decreased OVA induced IL-13 in sensitized mice (Fig. 5C). Airway mucus hypersecretion is also linked to IL-13 and is a major pathophysiological feature of both allergic asthma and whooping cough. It is not surprising therefore that mucus production mirrored IL-13 levels in this study and was significantly reduced in sensitized mice previously exposed to BPZE1 (Fig 5C).
This study suggests that one, or a combination, of the attenuated virulence factors in BPZE1 (pertussis toxin, tracheal cytotoxin and dermonecrotic toxin) play a role in the adjuvant effect observed with virulent B. pertussis strains, via the induction of either IL-5 or IL-13, or both.
The protection against allergen-driven pathology seen here is associated with three genetic modifications contained within BPZE1 and modulation of the allergic immune response is consistent with some versions of the hygiene hypothesis. However, the mechanisms underlying the beneficial influence of attenuated BPZE1 on allergen-driven pathology may be multiple and interlinked. Previous studies have demonstrated a significant increase in total serum IgE as a result of OVA sensitization in animal models (Holgate et al. J Allergy Clin Immunol 2005; 115(3):459-465; Hamelmann et al. Allergy 1999;54(4):297-305). Here, allergen-specific IgE responses induced by respiratory sensitization were significantly reduced in mice receiving attenuated compared to virulent B. pertussis. This is consistent with the modulation of systemic immune responses to OVA induced by attenuated BPZE1 away from IL-5 and IL-13 towards IFN-γ, a response which is associated with reduced IgE (Lack et al. J Immunol 1994; 152(5):2546-54). Nevertheless allergic airway inflammation is not simply a balance between Th1 and Th2 responses. Hansen et al have shown that modulation of airway CD4+ Th responses does not necessarily reduce airway pathology (Hansen et al. J Clin Invest 1999; 103(2): 175-183). It might be that the key beneficial feature of BPZE1 is the combination of a Th1 skewed response combined with the absence of induced airway pathology. This is consistent with previous reports in which exacerbation of airway pathology to allergen was associated with allergen priming during a period of airway damage or remodelling (Marsland et al. Clin Exp Allergy 2004;34(8):1299-306; Gern. J Allergy Clin Immunol 2000:105(2 Pt 2):S497-502).
This combined benefit makes live attenuated Bordetella pertussis vaccine which is deficient for TCT, PTX, and DNT an attractive candidate as a protective agent against atopy.
References [0029] Throughout this application, various references describe the state of the art to which this invention pertains.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • VVQ200710445ΙΑ [0007]
Non-patent literature cited in the description . ROMAGNANI et al.J Allergy Clin Immunol, 2004, vol. 113, 3395-400 [00021 • ROMAGNANI et al.lnt Arch Allergy Immunol, 1992, vol. 98, 4279-85 [0002] . ENNIS et al.Clin Exp Allergy, 2004, vol. 34, 91488-97 [00021 [00021 [00171 [00181 [00221 [00231 [0024] [00271 . DAS P.Lancet Infect Dis, 2002, vol. 2, 6322- [0002] • ENNIS et al.Clin Diagn Lab Immunol, 2005, vol. 12, 3409-17 [0002] [0018] . MILLS et al.Dev Biol Stand., 1998, vol. 95, 31-41 [00021 [00171 [00281 • MIELCAREK et al.PLoS Pathog, 2006, vol. 2, 765- [0002] [0007] • MASCART et al.J Immunology, 2003, vol. 170, 11504-9 [0002] • SI YING HO et al.Infection and Immunity, 2008, vol. 76, 1111-119 [00101 . MAHON et al.J Exp Med, 1997, vol. 186, 111843-1851 [0019] • MOROKATATETImmunology, 1999, vol. 98, 3345-351 [00201 . HARJU et al.Thorax, 2006, vol. 61, 7579-584 [0022] . GRLIBER et al.Allergy, 2008, vol. 63, 111464-72 [00281 • MARTIGNONetal.Pediatr Allergy Immunol., 2005, vol. 16,3193-200 [0028] • GLEICH G.J Allergy Clin Immunol, 2000, vol. 105, 4651 -63 [0028] • HUMBERT et al.J Allergy Clin Immunol., 1997, vol. 99, 5657-65 [0028] • TEMANN et al.Am J Respir Cell Mol Biol, 1997, vol. 16, 4471-8 [0028] • HOLGATE et al.J Allergy Clin Immunol, 2005, vol. 115, 3459-465 [0028] • HAM ELM ANN et al.Allergy, 1999, vol. 54. 4297-305 [00281 • LACK et al.J Immunol, 1994, vol. 152, 52546-54 [0028] • HANSEN et al.J Clin Invest, 1999, vol. 103, 2175-183 [00281 . MARSLAND et al.Clin Exp Allergy, 2004, vol. 34, 81299-306 [0028] • Gern. J Allergy Clin Immunol, 2000, vol. 105, 497-502 [0028]
Claims (6)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305371 | 2009-04-28 | ||
| PCT/EP2010/055507 WO2010125014A1 (en) | 2009-04-28 | 2010-04-26 | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2424564T3 true DK2424564T3 (en) | 2015-04-27 |
Family
ID=41057387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10715245T DK2424564T3 (en) | 2009-04-28 | 2010-04-26 | A vaccine for the prevention or treatment of a respiratory pathology allergendrevet |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US20120177688A1 (en) |
| EP (3) | EP2910252A1 (en) |
| JP (1) | JP5678034B2 (en) |
| CN (1) | CN102448490B (en) |
| AU (1) | AU2010243708C1 (en) |
| CA (1) | CA2759280C (en) |
| DK (1) | DK2424564T3 (en) |
| ES (2) | ES2535412T3 (en) |
| SG (1) | SG175803A1 (en) |
| WO (1) | WO2010125014A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800244A1 (en) * | 2006-03-10 | 2021-04-07 | Institut Pasteur de Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| US20120177688A1 (en) | 2009-04-28 | 2012-07-12 | Institut Pasteur De Lille | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology |
| DK2442826T3 (en) | 2009-06-15 | 2015-09-21 | Univ Singapore | Influenza vaccine, composition and methods of using |
| ES2781481T3 (en) * | 2011-11-02 | 2020-09-02 | Nat Univ Singapore | Effect of an attenuated Bordetella strain against allergic diseases |
| EP2722338A1 (en) | 2012-10-17 | 2014-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel recombinant Bordetella strains |
| WO2015024022A2 (en) | 2013-08-16 | 2015-02-19 | University Of Rochester | Designed peptides for tight junction barrier modulation |
| US9655959B2 (en) * | 2014-10-01 | 2017-05-23 | National University Of Singapore | Adenylate cyclase deficient bordetella strains |
| US10682377B2 (en) * | 2016-03-29 | 2020-06-16 | Institut Pasteur De Lille | Mutant Bordetella strains and methods of use |
| JP6598724B2 (en) | 2016-04-07 | 2019-10-30 | 株式会社ジェイテクト | Steering device |
| CN111278456B (en) | 2017-10-18 | 2024-08-09 | 里尔巴斯德研究所 | Bordetella strains expressing serotype 3 pili |
| EP3980054A1 (en) | 2019-06-05 | 2022-04-13 | University Of Rochester | New designed inhibitors of tight junction formation |
| EP3909971A1 (en) | 2020-09-28 | 2021-11-17 | Institute of Life Sciences (ILS) | Whole cell livestock vaccine for respiratory diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4883761A (en) | 1986-03-25 | 1989-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
| US5101019A (en) * | 1987-05-22 | 1992-03-31 | Takeda Chemical Industries, Ltd. | Method for removing pertussis endotoxin, a pertussis toxoid and its production |
| US6713072B1 (en) | 1987-11-02 | 2004-03-30 | Chiron S.R.L. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
| GB9115332D0 (en) | 1991-07-16 | 1991-08-28 | Connaught Lab | Manipulation of gene copy number in bordetella |
| FR2754543B1 (en) | 1996-10-11 | 1998-12-31 | Pasteur Institut | BORDETELLA STRAIN DEFICIENT IN TOXIN PRODUCTION AND EXPRESSING HYDRID PROTEIN, LIPOSOMES COMPRISING FHA AND THEIR USES AS VACCINES, AND THE USE OF FHA TO STIMULATE IMMUNE RESPONSES |
| FR2840319B1 (en) * | 2002-05-30 | 2004-08-20 | Pasteur Institut | BORDETELLA STRAINS MADE DEFICIENT BY GENETIC ATTENUATION |
| WO2004091519A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Methods of preventing or treating respiratory conditions |
| GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
| EP3800244A1 (en) | 2006-03-10 | 2021-04-07 | Institut Pasteur de Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| WO2008118592A2 (en) | 2007-02-23 | 2008-10-02 | The Penn State Research Foundation | Use of an avirulent bordetella mutant as a live vaccine vector |
| CN100537767C (en) * | 2007-04-29 | 2009-09-09 | 中国药品生物制品检定所 | Recombinant expressed and the application of pertussis vaccine protective antigen |
| US20120177688A1 (en) | 2009-04-28 | 2012-07-12 | Institut Pasteur De Lille | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology |
| CN101947323B (en) * | 2010-07-26 | 2013-02-27 | 北京绿竹生物制药有限公司 | Gram negative bacterium vaccine and preparation method thereof |
| ES2781481T3 (en) | 2011-11-02 | 2020-09-02 | Nat Univ Singapore | Effect of an attenuated Bordetella strain against allergic diseases |
| EP2722338A1 (en) | 2012-10-17 | 2014-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel recombinant Bordetella strains |
| US9655959B2 (en) | 2014-10-01 | 2017-05-23 | National University Of Singapore | Adenylate cyclase deficient bordetella strains |
| US10682377B2 (en) | 2016-03-29 | 2020-06-16 | Institut Pasteur De Lille | Mutant Bordetella strains and methods of use |
| US10799573B2 (en) | 2016-03-30 | 2020-10-13 | Regents Of The University Of Minnesota | Pertussis vaccines and methods of making and using |
| WO2018213361A1 (en) | 2017-05-15 | 2018-11-22 | Vanderbilt University | LONG-CIRCULATING ZWITTERIONIC POLYPLEXES FOR siRNA DELIVERY |
| SG11202000224SA (en) | 2017-07-18 | 2020-02-27 | Serum Inst Of India Pvt Ltd | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
| CN111278456B (en) | 2017-10-18 | 2024-08-09 | 里尔巴斯德研究所 | Bordetella strains expressing serotype 3 pili |
| US12036405B2 (en) | 2018-03-23 | 2024-07-16 | The Board Of Regents Of The University Of Oklahoma | System and method of electric-induced acoustic tomography for electrotherapy monitoring |
-
2010
- 2010-04-26 US US13/266,561 patent/US20120177688A1/en not_active Abandoned
- 2010-04-26 DK DK10715245T patent/DK2424564T3/en active
- 2010-04-26 EP EP15154206.5A patent/EP2910252A1/en not_active Ceased
- 2010-04-26 WO PCT/EP2010/055507 patent/WO2010125014A1/en active Application Filing
- 2010-04-26 AU AU2010243708A patent/AU2010243708C1/en active Active
- 2010-04-26 ES ES10715245.6T patent/ES2535412T3/en active Active
- 2010-04-26 SG SG2011078771A patent/SG175803A1/en unknown
- 2010-04-26 ES ES19176782T patent/ES3024937T3/en active Active
- 2010-04-26 EP EP19176782.1A patent/EP3590532B1/en active Active
- 2010-04-26 EP EP10715245.6A patent/EP2424564B1/en active Active
- 2010-04-26 CA CA2759280A patent/CA2759280C/en active Active
- 2010-04-26 CN CN201080019636.0A patent/CN102448490B/en active Active
- 2010-04-26 JP JP2012507703A patent/JP5678034B2/en active Active
-
2013
- 2013-03-01 US US13/782,754 patent/US8986709B2/en active Active
-
2015
- 2015-01-30 US US14/609,461 patent/US9839683B2/en active Active
-
2017
- 2017-11-01 US US15/800,921 patent/US10420827B2/en active Active
-
2019
- 2019-08-09 US US16/537,342 patent/US10653765B2/en active Active
-
2020
- 2020-04-03 US US16/840,276 patent/US11110161B2/en active Active
-
2021
- 2021-08-02 US US17/392,066 patent/US11819545B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102448490B (en) | 2015-05-13 |
| US20190358309A1 (en) | 2019-11-28 |
| US20180085450A1 (en) | 2018-03-29 |
| EP3590532A1 (en) | 2020-01-08 |
| US20210361759A1 (en) | 2021-11-25 |
| JP2012525346A (en) | 2012-10-22 |
| CN102448490A (en) | 2012-05-09 |
| US20150182614A1 (en) | 2015-07-02 |
| AU2010243708C1 (en) | 2014-10-02 |
| AU2010243708B2 (en) | 2014-06-12 |
| CA2759280C (en) | 2016-09-20 |
| EP2910252A1 (en) | 2015-08-26 |
| CA2759280A1 (en) | 2010-11-04 |
| ES2535412T3 (en) | 2015-05-11 |
| AU2010243708A1 (en) | 2011-11-03 |
| EP2424564B1 (en) | 2015-02-25 |
| WO2010125014A1 (en) | 2010-11-04 |
| US9839683B2 (en) | 2017-12-12 |
| SG175803A1 (en) | 2011-12-29 |
| US11110161B2 (en) | 2021-09-07 |
| EP2424564A1 (en) | 2012-03-07 |
| EP3590532C0 (en) | 2025-03-19 |
| US8986709B2 (en) | 2015-03-24 |
| US20120177688A1 (en) | 2012-07-12 |
| US20130183336A1 (en) | 2013-07-18 |
| US10420827B2 (en) | 2019-09-24 |
| US11819545B2 (en) | 2023-11-21 |
| JP5678034B2 (en) | 2015-02-25 |
| US10653765B2 (en) | 2020-05-19 |
| EP3590532B1 (en) | 2025-03-19 |
| US20200282041A1 (en) | 2020-09-10 |
| ES3024937T3 (en) | 2025-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11819545B2 (en) | Vaccine for prophylaxis or treatment of an allergen-driven airway pathology | |
| US20250032600A1 (en) | Attenuated Bordetella Strains | |
| HK40048647A (en) | Live attenuated bordetella strains as a single dose vaccine against whooping cough | |
| HK1226777A1 (en) | Live attenuated bordetella strains as a single dose vaccine against whooping cough | |
| HK1124090B (en) | Live attenuated bordetella strains as a single dose vaccine against whooping cough |